コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 l responses is desired (ie, in anti-viral or anti-tumor immunity).
2 ly replicates in cancer cells while inducing anti-tumor immunity.
3 hibitory Siglecs that can potentially dampen anti-tumor immunity.
4 an important role in immune surveillance and anti-tumor immunity.
5 ce protective, antigen-specific CTL-mediated anti-tumor immunity.
6 ry strategies aimed at inducing antiviral or anti-tumor immunity.
7 ce may be key in the generation of effective anti-tumor immunity.
8 e attenuation as well as the facilitation of anti-tumor immunity.
9 cells and their ability to induce efficient anti-tumor immunity.
10 reprogrammed into indispensable mediators of anti-tumor immunity.
11 nogenicity and its role in the activation of anti-tumor immunity.
12 une disease and graft rejection and promotes anti-tumor immunity.
13 -activating TLR4 agonist capable of inducing anti-tumor immunity.
14 austion ligands and thereby negated adaptive anti-tumor immunity.
15 ion of tumor antigens and thereby stimulates anti-tumor immunity.
16 ted role of the Hippo pathway in suppressing anti-tumor immunity.
17 modeling, and impairment of T cell-dependent anti-tumor immunity.
18 tes to reveal a role for zinc homeostasis in anti-tumor immunity.
19 reg) cells pose a major barrier to effective anti-tumor immunity.
20 (Th1) immune responses that are required for anti-tumor immunity.
21 ific alphabeta T cell receptor (TCR) mediate anti-tumor immunity.
22 astatic niche formation and the induction of anti-tumor immunity.
23 ved to be a major contributor to compromised anti-tumor immunity.
24 promoting T cell function, autoimmunity, and anti-tumor immunity.
25 ting T cell function during autoimmunity and anti-tumor immunity.
26 glucose availability to T cells, suppressing anti-tumor immunity.
27 iggers Treg instability locally and restores anti-tumor immunity.
28 in tumor-infiltrating dendritic cells blunts anti-tumor immunity.
29 varian cancer (OvCa) progression by blunting anti-tumor immunity.
30 alignant melanoma, by impeding IgG1-mediated anti-tumor immunity.
31 l of cancer cells, as well as in suppressing anti-tumor immunity.
32 mal tissues function in parallel to restrict anti-tumor immunity.
33 lly provide therapeutic benefit by enhancing anti-tumor immunity.
34 a pathophysiological context: suppression of anti-tumor immunity.
35 the tumor microenvironment that can suppress anti-tumor immunity.
36 into the mechanism by which OX40 may impact anti-tumor immunity.
37 seek to reverse this phenomenon and promote anti-tumor immunity.
38 ancer membrane target antigens using humoral anti-tumor immunity.
39 ls into the tumor microenvironment restrains anti-tumor immunity.
40 earch indicates that B cells are involved in anti-tumor immunity.
41 ntion of autoimmunity and the suppression of anti-tumor immunity.
42 ze SERCA function to disable T cell-mediated anti-tumor immunity.
43 miting the generation of innate and adaptive anti-tumor immunity.
44 ion, regulating the balance between pro- and anti-tumor immunity.
45 is the bottleneck, which precludes efficient anti-tumor immunity.
46 es rapid vessel loss, which does not support anti-tumor immunity.
47 r-infiltrating T cells results in diminished anti-tumor immunity.
48 nisms of immunosuppression hinder productive anti-tumor immunity.
49 Treg cells into tumor-bearing mice enhanced anti-tumor immunity.
50 Regulatory T cells (Tregs) are a barrier to anti-tumor immunity.
51 s NK cells and augments antigen-specific CTL anti-tumor immunity.
52 nting DCs strongly enhances antigen-specific anti-tumor immunity.
53 rived cytokines with the capacity to augment anti-tumor immunity.
54 critical role in both afferent and efferent anti-tumor immunity.
55 e balance of the immune response in favor of anti-tumor immunity.
56 F-beta signaling leads to the enhancement of anti-tumor immunity.
57 vitamin D signaling in humans could suppress anti-tumor immunity.
58 ciated antigens for the induction of in vivo anti-tumor immunity.
59 or psoriasis, but pDCs are also involved in (anti-)tumor immunity.
61 resent tumor-associated antigens for in vivo anti-tumor immunity against challenge with the S1509a sp
62 seful for enlisting the help of DCs to boost anti-tumor immunity against local and metastatic tumors
63 ellular immunity and failed cytotoxic T cell anti-tumor immunity, alter cancer risk and therefore rep
64 cells are important and potent mediators of anti-tumor immunity and adoptive transfer of specific CD
65 ly unappreciated roles for IL-35 in limiting anti-tumor immunity and contributing to T cell dysfuncti
66 gnaling pathways, can contribute to decrease anti-tumor immunity and enhance cell proliferation and o
67 umor microenvironment lead to eradication of anti-tumor immunity and enhanced tumor cell survival.
68 t a pro-inflammatory environment may curtail anti-tumor immunity and favor cancer initiation and prog
69 for the stimulation of CD4+ T cell dependent anti-tumor immunity and may play a role in tumor surveil
70 and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressio
71 3 with other check-point inhibitors enhances anti-tumor immunity and suppresses tumor growth in sever
73 trated that Cu- and Zn-AMSs markedly induced anti-tumor-immunity and enhanced CD4(+) and CD8(+) T cel
74 ility of surrounding wild-type Tregs, boosts anti-tumor immunity, and facilitates tumor clearance.
76 r-derived Ags leading to long-lived systemic anti-tumor immunity, and suggests a paradigm for clinica
78 ntributes to the protection against the host anti-tumor immunity as well as to the survival of invadi
79 ens for the induction of substantial in vivo anti-tumor immunity but only after activation in vitro b
81 ents with immunogenic properties may enhance anti-tumor immunity by inducing autophagic cell death.
83 ed peptide ligands in order to induce strong anti-tumor immunity capable of breaking tolerance toward
84 Modulation of the immune system to amplify anti-tumor immunity carries the risk of developing autoi
85 vivo, restoration of TTP expression enhances anti-tumor immunity dependent on degradation of PD-L1 mR
86 a mature immune system, we detect measurable anti-tumor immunity from very early stages, which is dri
87 landscape of a tumor shapes and is shaped by anti-tumor immunity has not been systematically explored
89 ted control of TH9 differentiation regulated anti-tumor immunity in an experimental melanoma-bearing
92 epletion of CD8, but not CD4 T cells reduced anti-tumor immunity, indicating CTL as the effector cell
94 r, its immunomodulatory activities to induce anti-tumor immunity predict the suppression of tumor gro
96 aptive cytotoxic effector response away from anti-tumor immunity ('sword') and towards proinflammator
98 e that instead impede development of desired anti-tumor immunity, thus providing synergistic effects
99 role for tumor-derived HSP70 in facilitating anti-tumor immunity to limit tumor growth and highlight
100 in the regulation of processes ranging from anti-tumor immunity to the adjuvant action of aluminum h
101 s that RNA-pulsed epidermal cells can induce anti-tumor immunity, total cellular RNA was isolated fro
102 STAT6 gene facilitates development of potent anti-tumor immunity via a CD4(+)-independent pathway.
103 nd mRNA expression for genes associated with anti-tumor immunity were obtained from the invasive brea
104 ivated CD4(+) T cells, promotes and enhances anti-tumor immunity with limited success on large tumors
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。